Cohance expects FY27 recovery after low Q1, margin pressure persists

Cohance Lifesciences Limited — Q4 & FY26 Earnings Call (Quarter & Year ended Mar 31, 2026; call held May 12, 2026)

1. Overall Tone of Management: Neutral (with pockets of optimism)

• Management is confident about medium-term recovery (“growth will return from second half of FY27 onwards”, “bottoming out phase”, “recovery becoming more visible from second half of FY27”).
• However, they repeatedly emphasize near-term weakness and uncertainty: Q1 FY27 “to be low on both revenue and EBITDA”, FY26 decline, and margin pressure from Middle East logistics/freight and input costs plus destocking/customer-specific issues.

2. Key Themes from Management Commentary

• Strategic reset / blueprinting under new leadership
• CEO/Chairman Umang Vohra: “By the end of this fiscal year, the intent is to create a strategic blueprint for growth and sustainable value creation.”
• Focus on predictability of delivery via quality systems, talent, and a “pipeline that matters”.
• FY26 performance impacted by non-recurring and operational factors
• Pharma CDMO: “destocking impact”, “order phasing”, “slower reloads”.
• API+: decline due to “shipment delays” and “temporary disruption at the Nacharam formulation site”.
• Specialty chemicals: “customer program phasing, regulatory timing, and generic pressure”.
• Pipeline and conversion focus for FY27
• CDMO: Phase 3 pipeline expanded to 10 programs; reload conversion “quite high above 90%”; “order conversion… healthy”.
• NJ Bio (ADC): capex expansion “$10 million” progressing for scale-up/validation readiness.
• Oligonucleotides (Sapala): follow-on PO; cGMP building block facility under validation; “more than 20 audits and customer visits”.
• Cost/margin management + capex discipline
• Capex: FY26 INR 2.15 bn, FY27 expected ~INR 3 bn (ADC/oligos/manufacturing infrastructure/quality).
• Margin pressure: Q1 FY27 gross margin impact “nearly 100 to 150 bps” due to Middle East logistics/input cost; selective inflation and freight escalation.
• Customer relationship rebuilding and de-risking concentration
• Management acknowledges concentration-driven “vacuum” after loss of two commercial molecules and emphasizes widening customer/project pipeline.

3. Q&A Analysis

Theme A: CDMO revenue bridge, molecule contribution, and visibility

• Core questions
• FY26 CDMO revenue split by ADC / small molecules / Sapala / NJ Bio; expected return in FY27 from the two destocked commercial molecules; contribution from newly commercialized products.
• ADC contribution and growth outlook.
• Management response
• Destocking impact quantified: “impact is around INR260 crore.”
• Return in FY27: they say they expect return but won’t quantify: “we expect there would be a return… However… we cannot confirm… the actual amount.”
• New products: one product has “four commercial orders… revenue… mostly in Q2 FY27 and Q3 FY27”; second product timing under discussion.
• ADC contribution color: explicitly refused—“we are not providing that color right now.”
• Evasiveness / partial answers
• Multiple requests for quantification were met with non-commitment (no ADC %/growth, no FY27 value of returning molecules).

Theme B: FY27 guidance mechanics (H1 vs H2, segment sequencing)

• Core questions
• What qualitative/tangible drivers support Q1 weakness and H2 recovery?
• Segment-by-segment color (Spec Chem, API Plus, CDMO).
• Benchmarking growth: FY25 base vs higher base.
• Management response
• Sequencing: “API followed by CDMO and followed by Spec Chem.”
• Q1 low: “quarter 1… weak… both revenue and EBITDA”; Q2 stable; H2 growth.
• Benchmarking: growth is YoY; they cite lag due to commercial pipeline ramp and “lag effect on the revenue”.
• Notable strength
• Clear articulation of timing (Q1 low, Q2 stable, H2 recovery) and lag mechanics.

Theme C: Margin normalization timeline and consolidated margin benchmark

• Core questions
• When will consolidated margins return to historical ~30%?
• Details on Sapala/NJ Bio and timeline to profitability.
• Management response
• They point to standalone vs consolidated gap: “4% to 5% play”.
• Sapala: reload on Phase 2/3 should accelerate.
• NJ Bio: profitability recovery takes time; “give us… maybe more than two years to get back to this level.”
• Red flag in answer
• Margin recovery is pushed out (explicitly >2 years for NJ Bio), implying consolidated margin may remain structurally pressured longer than investors may expect.

Theme D: AI / operational efficiency and regulatory filing acceleration

• Core questions
• Examples of AI implementation improving speed/quality; any FY27 impact.
• Management response
• AI used for “analysis” and “proper communication with clients”.
• Evaluating tools for “operational efficiencies” and “reducing our time to file” plus regulatory quality.
• Evasive element
• No quantified productivity gains or timeline for measurable benefits.

Theme E: Expense “one-offs” and cost structure

• Core questions
• Breakdown of one-time expenses (~INR109 crore over two years).
• Breakdown of “other expenses” (~INR671 crore) and whether brand-building is one-time.
• Management response
• One-time: inventory provision “around 195 million” and customer adjustments “around 126 million” (note: the question referenced INR109 crore; answer focused on FY26 elements).
• Other expenses: major portion is “conversion expenditure… INR400 plus Crore”; balance includes “marketing expenditure… merger… brand building” and SG&A.
• Brand building reduction expected: “yes, we would see a reduction…” but no quantification.
• Partial/unclear
• Some mismatch risk: investor asked for a specific two-year one-off figure; management answered with FY26 components and different numbers.

Theme F: Program pipeline counts and phase distribution

• Core questions
• Customer/program concentration by molecule/customer (top 1/3/5).
• Breakdown of programs by phase (Phase 1/2/3/commercial).
• Management response
• Concentration: they do not provide molecule/customer-level detail; instead state concentration is improving.
• Phase distribution: they refer to quarterly reporting and avoid giving a full breakdown in the call; they emphasize Phase 1/2 quality and that Phase 1/2 onboarding is strong.

Theme G: Corporate governance / information flow

• Core questions
• Whether Umang will strengthen governance and information flow after perceived selective disclosures and investor churn.
• Management response
• Commitment: “governance requirement is paramount… spending time on that”.
• Positive but non-specific
• No concrete governance actions/timeline beyond “two quarters down the line” offer.

4. Guidance / Outlook

Explicit guidance (quantitative / time-bound)

• FY27 margin & earnings shape
• Q1 FY27: “low on both revenue and EBITDA”.
• Q2 FY27: “stable”.
• H2 FY27: “growth will return” and “recovery becoming more visible”.
• Gross margin impact
• Q1 FY27 gross margin: “impact of nearly 100 to 150 bps on our FY26 gross margin levels” due to Middle East logistics/freight and input cost.
• Capex
• FY27 capex expected: “nearly INR 3 billion”.
• Cash flow
• FY26 free cash generated: INR 1.73 bn (historical), no FY27 cash guidance beyond recovery narrative.
• Growth
• “growth will return from second half of FY27 onwards” (no numeric growth % given).

Implicit signals (qualitative)

• Recovery drivers
• “execution on existing programs, customer conversions, reloads, and improving utilization”.
• Operational stabilization
• API Plus: supply execution stabilized; formulation site remediation strengthening quality; “expect further normalization”.
• Pipeline conversion lag
• Management repeatedly highlights lag effect from pipeline additions to revenue realization (commercialization timing depends on customers/clinical progress).

5. Standout Statements (direct / high-signal)

• Strategic blueprint
• “By the end of this fiscal year, the intent is to create a strategic blueprint for growth and sustainable value creation.”
• Near-term earnings trough
• “Q1 FY27 is to be low on both revenue and EBITDA…”
• “We believe the business is moving towards a bottoming out phase, with Q1 FY27 to be the low point.”
• Margin pressure
• “Q1 will experience impact of nearly 100 to 150 bps on our FY26 gross margin levels…”
• Destocking quantified
• “impact is around INR260 crore” (two large commercial molecules).
• Reload strength
• “Reload conversion remains quite high above 90%”
• NJ Bio profitability timeline
• “give us… more than two years to get back to this level” (to historical consolidated margin benchmark context).
• Refusal to quantify ADC
• “we are not providing that color right now” (ADC contribution and growth).

6. Red Flags / Positive Signals

Red flags
– Quantification gaps / visibility limits
– Multiple “we expect” statements without numbers (return amount from destocked molecules; ADC contribution; FY27 growth %).
– Margin recovery delayed
– NJ Bio profitability/margin normalization pushed to >2 years, suggesting consolidated margin may not revert quickly.
– Potential mismatch in one-off expense framing
– Investor asked for breakdown of ~INR109 crore over two years; management provided FY26 one-time components with different figures (inventory provision and customer adjustments).
– AI benefits not evidenced
– AI described as tools for analysis/filings, but no measurable outcomes.

Positive signals
– Operational stabilization claims
– API Plus: supply execution stabilized; remediation strengthening quality systems.
– Pipeline momentum
– Phase 3 pipeline increased to 10; multiple Phase 3 and commercialization steps underway.
– Reload conversion strength
– “above 90%” supports resilience of ongoing commercial supply mechanics.
– Customer engagement intensity
– “more than 20 audits and customer visits” for oligonucleotides; senior customer teams visiting facilities.

7. Historical Comparison & Consistency Analysis (vs prior 3 calls provided)

a. Change in Tone Over Time

• Current call tone vs prior (FY25 Q4 / Q1 FY26)
• Prior calls (FY25 Q4, Q1 FY26) were more confident about acceleration and margin targets (e.g., FY26 “low 30s” EBITDA margin guidance in FY25 Q4 call; Q1 FY26 emphasized strong momentum excluding destocking).
• Current call is more cautious on near-term: explicit “bottoming out” and Q1 FY27 trough, plus Middle East cost headwinds.
• Classification shift: More Cautious
• Increased emphasis on timing lag, customer-specific destocking, and delayed margin normalization (NJ Bio >2 years).

b. Tracking Past Commitments vs Outcomes

• Commitment: FY26 acceleration / double-digit growth narrative (FY25 Q4 call)
• Expected: FY26 “pivotal year of acceleration and execution” with double-digit growth.
• Outcome (current call): FY26 revenue INR 22.68 bn, down ~13% YoY; API+ down 8%; Pharma CDMO impacted by destocking/order phasing.
• Flag: ❌ Missed / materially underperformed vs the acceleration narrative.
• Commitment: FY26 EBITDA margin “low 30s” (FY25 Q4 call)
• Expected: low 30s EBITDA margin.
• Outcome (current call): adjusted EBITDA margin 21% (standalone adjusted EBITDA margin 24.6%); gross margin 70.8% but operating margins pressured by volumes/investment/subsidy weakness.
• Flag: ❌ Missed (large gap vs “low 30s”).
• Commitment: Oligo cGMP building block facility validation timeline (Q1 FY26 call)
• Expected: cGMP oligonucleotide building block facility at Nacharam “expected to be fully operational by end of CY ’25” (Q1 FY26).
• Outcome (current call): facility “under validation”; multiple audits/qualifications progressing (still not fully commercialized).
• Flag: ⏳ Delayed / not fully realized by FY26 end (at least in terms of commercialization readiness).

c. Narrative Shifts

• From “platform acceleration” to “bottoming out + lag effects”
• Earlier: emphasis on growth engines “all firing” and margin recovery via operating leverage.
• Now: emphasis on H1 weakness, H2 recovery, and customer-driven lag from commercialization and reload conversion.
• Margin narrative shifted
• Earlier: mid-30s EBITDA margin target with scale.
• Now: consolidated margin benchmark (~30%) recovery explicitly depends on NJ Bio profitability taking >2 years.
• Less emphasis on specific growth targets
• Earlier calls discussed revenue growth/margin targets more directly; current call avoids numeric FY27 growth guidance.

d. Consistency & Credibility Signals

• Credibility: Low to Medium
• Pattern of over-optimistic medium-term framing in FY25/Q1 FY26 (acceleration, low-30s EBITDA margin) followed by material FY26 deterioration and delayed margin normalization.
• Explanations now are more detailed (destocking, site disruption, Middle East logistics), but the magnitude of misses reduces confidence.

e. Evolution of Key Themes

• Demand / destocking
• Deterioration in FY26 attributed to two commercial molecules; now framed as customer inventory adjustments with expected return.
• Margins
• Deteriorating in FY26; recovery pushed out with explicit bps headwinds and NJ Bio timeline.
• Expansion / capex
• Continued capex commitment (FY27 ~INR 3 bn) into ADC/oligos/quality—consistent with long-term strategy, but near-term margin impact acknowledged.
• Customer engagement
• Increasing emphasis on audits, senior visits, and conversion—consistent theme, but not yet translating into FY26 financial outcomes.

f. Additional Insights (cross-period intelligence)

• “Lag effect” is now central
• Management explicitly ties pipeline progress to revenue timing (“lag effect on the revenue”), suggesting earlier growth expectations may have underestimated commercialization timing and customer inventory cycles.
• Concentration risk acknowledged more directly
• Current call: “vacuum” after loss of two molecules; concentration de-risking is a stated priority—implies prior concentration risk was not fully reflected in earlier confidence.